Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice

References

• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11–20.
   PubMed Web of Science ®Google Scholar
• Stefan N, Haring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019 Apr;7(4):313–324.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019 Oct;71(4):793–801.
   PubMed Web of Science ®Google Scholar
• Schattenberg JM, Lazarus JV, Newsome PN, et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (nash) in five European countries in 2018: a cost-of-illness analysis. Liver Int. 2021;41(6):1227–1242.
   PubMed Web of Science ®Google Scholar
• O’Hara J, Finnegan A, Dhillon H, et al. Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study. JHEP Rep. 2020 Oct;2(5):100142.
   PubMedGoogle Scholar
• Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017 May;65(5):1557–1565.
   PubMed Web of Science ®Google Scholar
• Pearson-Stuttard J, Bennett J, YJ C, et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 2021;9(3):165–173.
   PubMed Web of Science ®Google Scholar
• Gregg EW, Cheng YJ, Srinivasan M, et al. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data. Lancet. 2018 Jun 16;391(10138):2430–2440.
   PubMed Web of Science ®Google Scholar
• Schattenberg JM, Straub BK. On the value and limitations of liver histology in assessing non-alcoholic steatohepatitis. J Hepatol. 2020 Dec;73(6):1592–1593.
   PubMed Web of Science ®Google Scholar
• Davison BA, Harrison SA, Cotter G, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol. 2020 Dec;73(6):1322–1332.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010 Jul;42(7):503–508.
   PubMedGoogle Scholar
• Koot BGP, van der Baan-Slootweg OH, Bohte AE, et al. Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children. Obesity (Silver Spring). 2013 Mar;21(3):583–590.
   PubMed Web of Science ®Google Scholar
• Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population [research support, non-U.SGov’t]. BMC Gastroenterol. 2006 Nov;2(6):33.
   Google Scholar
• Borman MA, Ladak F, Crotty P, et al. The fatty liver index has limited utility for the detection and quantification of hepatic steatosis in obese patients. Hepatol Int. 2013 Jun;7(2):592–599.
   PubMed Web of Science ®Google Scholar
• Poynard T, Lassailly G, Diaz E, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. PLoS ONE. 2012;7(3):e30325.
   PubMed Web of Science ®Google Scholar
• Poynard T, Lassailly G, Diaz E, et al. Performance of biomarkers fibrotest, actitest, steatotest, and nashtest in patients with severe obesity: meta analysis of individual patient data. PLoS One. 2012;7(3):e30325.
   PubMed Web of Science ®Google Scholar
• Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009 Sep;137(3):865–872.
   PubMed Web of Science ®Google Scholar
• Bedogni G, Kahn HS, Bellentani S, et al. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol. 2010 Aug;25(10):98.
   Google Scholar
• Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014 Nov;40(10):1209–1222.
   PubMed Web of Science ®Google Scholar
• Jung TY, Kim MS, Hong HP, et al. Comparative assessment and external validation of hepatic steatosis formulae in a community-based setting. J Clin Med. 2020;9(9):2851. DOI: https://doi.org/10.3390/jcm9092851.
   Google Scholar
• Foschi FG, Conti F, Domenicali M, et al. External validation of surrogate indices of fatty liver in the general population: the bagnacavallo study. J Clin Med. 2021 Feb 1;10:3.
   Web of Science ®Google Scholar
• Lazarus JV, Colombo M, Cortez-Pinto H, et al. NAFLD - sounding the alarm on a silent epidemic. Nat Rev Gastroenterol Hepatol. 2020 Jul;17(7):377–379.
   PubMed Web of Science ®Google Scholar
• Decharatanachart P, Chaiteerakij R, Tiyarattanachai T, et al. Application of artificial intelligence in chronic liver diseases: a systematic review and meta-analysis. BMC Gastroenterol. 2021 Jan 6;21(1):10.
   PubMed Web of Science ®Google Scholar
• Ma H, Xu CF, Shen Z, et al. Application of machine learning techniques for clinical predictive modeling: a cross-sectional study on nonalcoholic fatty liver disease in China. Biomed Res Int. 2018;2018:4304376.
   PubMed Web of Science ®Google Scholar
• Okanoue T, Shima T, Mitsumoto Y, et al. Artificial intelligence/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatol Res. 2021 May;51(5):554–569.
   PubMed Web of Science ®Google Scholar
• Sorino P, Caruso MG, Misciagna G, et al. Selecting the best machine learning algorithm to support the diagnosis of non-alcoholic fatty liver disease: a meta learner study. PLoS One. 2020;15(10):e0240867.
   PubMed Web of Science ®Google Scholar
• Wong GL, Yuen PC, Ma AJ, et al. Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis. J Gastroenterol Hepatol. 2021 Mar;36(3):543–550.
   PubMed Web of Science ®Google Scholar
• Yip TC, Ma AJ, Wong VW, et al. Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population. Aliment Pharmacol Ther. 2017 Aug;46(4):447–456.
   PubMed Web of Science ®Google Scholar
• Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011 Sep 2;54(3):1082–1090.
   PubMed Web of Science ®Google Scholar
• Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007 Dec;102(12):2708–2715.
   PubMed Web of Science ®Google Scholar
• Bril F, Ortiz-Lopez C, Lomonaco R, et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int. 2015 Sep;35(9):2139–2146.
   PubMed Web of Science ®Google Scholar
• Ballestri S, Nascimbeni F, Baldelli E, et al. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. Metabolism. 2017;72:57–65.
   PubMed Web of Science ®Google Scholar
• Ballestri S, Lonardo A, Romagnoli D, et al. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int. 2012 Sep;32(8):1242–1252.
   PubMed Web of Science ®Google Scholar
• Nelson SM, Hoskins JD, Lisanti C, et al. Ultrasound fatty liver indicator: a simple tool for differentiating steatosis from nonalcoholic steatohepatitis: validity in the average obese population. J Ultrasound Med. 2020 Apr;39(4):749–759.
   PubMed Web of Science ®Google Scholar
• Xavier SA, Monteiro SO, Arieira CM, et al. US-FLI score - Is it possible to predict the steatosis grade with an ultrasonographic score? Mol Genet Metab. 2021 Mar;132(3):204–209.
   PubMed Web of Science ®Google Scholar
• Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017 Nov;66(5):1486–1501.
   PubMed Web of Science ®Google Scholar
• Ballestri S, Nascimbeni F, Lugari S, et al. A critical appraisal of the use of ultrasound in hepatic steatosis. Expert Rev Gastroenterol Hepatol. 2019 Jul;13(7):667–681.
   PubMed Web of Science ®Google Scholar
• Ferraioli G, Soares Monteiro LB. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol. 2019 Oct 28;25(40):6053–6062.
   PubMed Web of Science ®Google Scholar
• Ballestri S, Tana C, Di Girolamo M, et al. Semi-Quantitative ultrasonographic evaluation of NAFLD. Curr Pharm Des. 2020;26(32):3915–3927.
   PubMed Web of Science ®Google Scholar
• Byra M, Han A, Boehringer AS, et al. Liver fat assessment in multiview sonography using transfer learning with convolutional neural networks. J Ultrasound Med. 2021 Mar;10. DOI: https://doi.org/10.1002/jum.15693.
   Google Scholar
• Han A, Byra M, Heba E, et al. Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat with radiofrequency ultrasound data using one-dimensional convolutional neural networks. Radiology. 2020 May;295(2):342–350.
   PubMed Web of Science ®Google Scholar
• Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009 Sep;51(3):433–445.
   PubMed Web of Science ®Google Scholar
• Kontrick AV, VanWagner LB, Yeh C, et al. Hepatic steatosis: an incidental finding that deserves attention. Acad Emerg Med. 2021 May;28(5):578–581.
   PubMed Web of Science ®Google Scholar
• Méndez-Sánchez N, Chavez-Tapia NC, Almeda-Valdes P. et al., The management of incidental fatty liver found on imaging. what do we need to do? Official journal of the American College of Gastroenterology | ACG. 2018;113:9.
   Web of Science ®Google Scholar
• European Association for the Study of the L. European Association for the study of d, European Association for the study of O. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388–1402.
   PubMed Web of Science ®Google Scholar
• Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010 Nov;36(11):1825–1835.
   PubMed Web of Science ®Google Scholar
• Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019 Jan;17(1):156–163 e2.
   PubMed Web of Science ®Google Scholar
• Wong VW, Chan WK, Chitturi S, et al. Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018 Jan;33(1):70–85.
   PubMed Web of Science ®Google Scholar
• Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005 Feb;288(2):E462–8.
   PubMed Web of Science ®Google Scholar
• Noureddin M, Lam J, Peterson MR, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013 Dec;58(6):1930–1940.
   PubMed Web of Science ®Google Scholar
• Stine JG, Munaganuru N, Barnard A, et al. Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020 Aug 31.
   PubMedGoogle Scholar
• Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017 Feb;152(3):598–607 e2.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Wilson LA, et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Network Open. 2019 Oct 2;2(10):e1912565.
   PubMed Web of Science ®Google Scholar
• Lee J, Vali Y, Boursier J, et al. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis. PLoS One. 2020;15(9):e0238717.
   PubMed Web of Science ®Google Scholar
• Anty R, Iannelli A, Patouraux S, et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther. 2010 Dec;32(11–12):1315–1322.
   PubMed Web of Science ®Google Scholar
• Grigorescu M, Crisan D, Radu C, et al. A novel pathophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis. J Physiol Pharmacol. 2012 Aug;63(4):347–353.
   PubMed Web of Science ®Google Scholar
• Walenbergh SM, Houben T, Hendrikx T, et al. Plasma cathepsin D levels: a novel tool to predict pediatric hepatic inflammation. Am J Gastroenterol. 2015 Mar;110(3):462–470.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005 Jun;41(6):1313–1321.
   PubMed Web of Science ®Google Scholar
• Poynard T, Ratziu V, Charlotte F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006 Nov;10(6):34.
   Google Scholar
• Zhou Y, Oresic M, Leivonen M, et al. Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites. Clin Gastroenterol Hepatol. 2016 Oct;14(10):1463–1472 e6.
   PubMed Web of Science ®Google Scholar
• Sumida Y, Yoneda M, Hyogo H, et al. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol. 2011 Feb;46(2):257–268.
   PubMed Web of Science ®Google Scholar
• Gholam PM, Flancbaum L, Machan JT, et al. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007 Feb;102(2):399–408.
   PubMed Web of Science ®Google Scholar
• Palekar NA, Naus R, Larson SP, et al. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int. 2006 Mar;26(2):151–156.
   PubMed Web of Science ®Google Scholar
• Alkhouri N, Berk M, Yerian L, et al. OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease. Dig Dis Sci. 2014 Jul;59(7):1617–1624.
   PubMed Web of Science ®Google Scholar
• Hyysalo J, Mannisto VT, Zhou Y, et al. A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol. 2014 Apr;60(4):839–846.
   PubMed Web of Science ®Google Scholar
• Boursier J, Anty R, Vonghia L, et al. Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH. Aliment Pharmacol Ther. 2018 May;47(10):1387–1396.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Ratziu V, Boursier J, et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020 Nov;5(11):970–985.
   PubMed Web of Science ®Google Scholar
• Loomba R, Wolfson T, Ang B, et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology. 2014 Dec;60(6):1920–1928.
   PubMed Web of Science ®Google Scholar
• Ajmera V, Loomba R. Can elastography differentiate isolated fatty liver from nonalcoholic steatohepatitis? Semin Liver Dis . 2018 Feb;38(1):14-20. DOI: https://doi.org/10.1055/s-0037-1618587.
   Google Scholar
• Besutti G, Valenti L, Ligabue G, et al. Accuracy of imaging methods for steatohepatitis diagnosis in non-alcoholic fatty liver disease patients: a systematic review. Liver Int. 2019 Aug;39(8):1521–1534.
   PubMed Web of Science ®Google Scholar
• Banerjee R, Pavlides M, Tunnicliffe EM, et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 2014 Jan;60(1):69–77.
   PubMed Web of Science ®Google Scholar
• Dennis A, Kelly MD, Fernandes C, et al. Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis. Front Endocrinol (Lausanne). 2020;11:575843.
   PubMed Web of Science ®Google Scholar
• Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020 May;158(6):1611–1625 e12.
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006 Jun;43(6):1317–1325.
   PubMed Web of Science ®Google Scholar
• Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1104–1112.
   PubMed Web of Science ®Google Scholar
• McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD Fibrosis. Am J Gastroenterol. 2017 May;112(5):740–751.
   PubMed Web of Science ®Google Scholar
• Labenz C, Huber Y, Kalliga E, et al. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Aliment Pharmacol Ther. 2018 Nov;48(10):1109–1116.
   PubMed Web of Science ®Google Scholar
• Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD [Validation Studies]. Hepatology. 2007 Apr;45(4):846–854.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008 Oct;57(10):1441–1447.
   PubMed Web of Science ®Google Scholar
• Cales P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005 Dec;42(6):1373–1381.
   PubMed Web of Science ®Google Scholar
• Poynard T, Imbert-Bismut F, Munteanu M, et al. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis? Expert Rev Mol Diagn. 2005 Jan;5(1):15–21.
   PubMed Web of Science ®Google Scholar
• Ampuero J, Pais R, Aller R, et al. Development and validation of hepamet fibrosis scoring system-a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis. Clin Gastroenterol Hepatol. 2020 Jan;18(1):216–225 e5.
   PubMed Web of Science ®Google Scholar
• Ballestri S, Mantovani A, Baldelli E, et al. Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease. Diagnostics (Basel). 2021;11(1):98. Published online 2021 Jan 9. DOI: https://doi.org/10.3390/diagnostics11010098.
   Google Scholar
• Karsdal MA, Hjuler ST, Luo Y, et al. Assessment of liver fibrosis progression and regression by a serological collagen turnover profile. Am J Physiol Gastrointest Liver Physiol. 2019 Jan 1;316(1):G25–G31.
   PubMed Web of Science ®Google Scholar
• Vali Y, Lee J, Boursier J, et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J Hepatol. 2020 Aug;73(2):252–262.
   PubMed Web of Science ®Google Scholar
• Glen J, Floros L, Day C, et al. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. BMJ. 2016 Sep;7(354):i4428.
   Google Scholar
• Are VS, Vuppalanchi R, Vilar-Gomez E, et al. Enhanced liver fibrosis score can be used to predict liver-related events in patients with nonalcoholic steatohepatitis and compensated cirrhosis. Clin Gastroenterol Hepatol. 2020;19(6):1292-1293.e3. DOI:https://doi.org/10.1016/j.cgh.2020.06.070.
   Google Scholar
• Huber Y, Pfirrmann D, Gebhardt I, et al. Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program. Aliment Pharmacol Ther. 2019 Oct;50(8):930–939.
   PubMed Web of Science ®Google Scholar
• Boyle M, Tiniakos D, Schattenberg JM, et al. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Rep. 2019 Sep;1(3):188–198.
   PubMedGoogle Scholar
• Friedrich-Rust M, Poynard T, Castera L. Critical comparison of elastography methods to assess chronic liver disease. Nat Rev Gastroenterol Hepatol. 2016 Jul;13(7):402–411.
   PubMed Web of Science ®Google Scholar
• Boursier J, Vergniol J, Guillet A, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol. 2016 Sep;65(3):570–578.
   PubMed Web of Science ®Google Scholar
• Kwok R, Tse YK, Wong GL, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease–the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014 Feb;39(3):254–269.
   PubMed Web of Science ®Google Scholar
• Singh S, Venkatesh SK, Wang Z, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol. 2015 Mar;13(3):440–451 e6.
   PubMed Web of Science ®Google Scholar
• Loomba R, Cui J, Wolfson T, et al. Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in nafld: a prospective study. Am J Gastroenterol. 2016 Jul;111(7):986–994.
   PubMed Web of Science ®Google Scholar
• Hsu C, Caussy C, Imajo K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. 2019 Mar;17(4):630–637.e8.
   PubMed Web of Science ®Google Scholar
• Park JG, Jung J, Verma KK, et al. Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2021 May;53(9):1030–1037.
   PubMed Web of Science ®Google Scholar
• *Loomba R, Neuschwander-Tetri BA, Sanyal A, et al. Multicenter validation of association between decline in MRI-PDFF and histologic response in NASH. Hepatology. 2020 Oct;72(4):1219–1229.
   PubMed Web of Science ®Google Scholar
• Cassinotto C, Boursier J, de Ledinghen V, et al. Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, fibroscan, and ARFI with liver biopsy. Hepatology. 2016 Jun;63(6):1817–1827.
   PubMed Web of Science ®Google Scholar
• Joo SK, Kim W, Kim D, et al. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease. Liver Int. 2018 Feb;38(2):331–341.
   PubMed Web of Science ®Google Scholar
• Herrmann E, de Ledinghen V, Cassinotto C, et al. Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: an individual patient data-based meta-analysis. Hepatology. 2018 Jan;67(1):260–272.
   PubMed Web of Science ®Google Scholar
• Singal AG, Manjunath H, Yopp AC, et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol. 2014 Mar;109(3):325–334.
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015 Feb;61(2):506–514.
   PubMed Web of Science ®Google Scholar
• Armandi A, Schattenberg JM. NAFLD between genes and environment: what drives fibrogenesis? Gut. 2020;70(5):815-816. DOI: https://doi.org/10.1136/gutjnl-2020-321964.
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Meroni M, Longo M, et al. miRNA signature in NAFLD: a turning point for a non-invasive diagnosis. Int J Mol Sci. 2018 Dec 10;19(12):3966.
   PubMed Web of Science ®Google Scholar
• Pirola CJ, Fernández Gianotti T, Castaño GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015 May;64(5):800–812.
   PubMed Web of Science ®Google Scholar